Navigation Links
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Date:6/21/2009

clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (including the failure to achieve the overall response rate, complete remissions and progression-free survival and the possibility of significant grade 3, 4 adverse effects, including cardiac disorders) for the treatment of relapsed, refractory indolent or aggressive NHL as determined by the FDA, the potential that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in six months or in the fourth quarter of 2009, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
5. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
6. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Cumberland Pharmaceuticals Inc. (NASDAQ: ... 2014 financial results after the market closes on Tuesday, ... webcast will be held on Tuesday, August 5, 2014, ... To participate in the call, please dial ... A rebroadcast of the teleconference will be available for ...
(Date:7/22/2014)... 22, 2014 The National Space Biomedical Research ... for Space Radiation Research (CSRR) under the leadership of ... Associate Professor of Pharmaceutical Sciences within the University of ... of Radiation Health. She is located in ... team of investigators working across four U.S. institutions, to ...
(Date:7/22/2014)... Resources Group finds that the market for interventional cardiology (IC) ... stagnant at a value of around $80 million through 2022. ... volumes are growing faster in Canada ... United States and Europe . ... penetration of PCI procedures relative to coronary artery bypass graft ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3
... Meghan Lopresto, VP, Sales Force Automation Analytics at The ... Vaccines, will be co-presenting their expertise in interactive selling ... in Philadelphia. The conference is a ... and medical affairs professionals to discuss novel approaches to ...
... -- In 2012, Fi Asia-China, Hi & Ni ... food & beverage shows in China, will take ... Shanghai New International Expo Centre (SNIEC), organized by ... ) (Logo: http://www.prnasia.com/sa/2010/04/19/20100419602891.jpg ) ...
Cached Medicine Technology:The CementBloc and Novartis Vaccines to Jointly Present Top Considerations in Interactive Selling at the 11th Annual iPharmaConnect 2Fi Asia-China, Hi & Ni China is Ready for Return on June 2012 in Shanghai 2
(Date:7/22/2014)... of Hematology (ASH) will present the Society,s highest honor, ... in Hematology, to Kanti R. Rai, MD, of the ... for his 50-year career combining landmark clinical leukemia research, ... care. , The Wallace H. Coulter Award for ... who has been a vital contributor to the field ...
(Date:7/22/2014)... Washington DC (PRWEB) July 22, 2014 ... in USA, launched updated payment app for Forte Payment ... credit, debit and ACH payments on iPhone, iPod and ... 2013 and has been recently updated by SIMpalm. This ... support; app is currently supported on iOS 4.3 and ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
(Date:7/22/2014)... The Pennsylvania judge overseeing hundreds ... in the Philadelphia Court of Common Pleas won’t ... cases alleging the medication caused plaintiffs to develop ... In an Order dated July 18, 2014, Judge ... certify the matter for an immediate appeal to ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) ... owing to novel medical indications created and due to ... societies where physical appearance is extremely valued. Although the ... competitors, new companies and technologies are setting ground for ... put the price of 1st-gen products under pressure, only ...
Breaking Medicine News(10 mins):Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... Annual Meeting & OTO EXPO of the American Academy of ... meeting of ear, nose, and throat doctors in the world, ... more than 305 scientific research sessions, 594 posters, and several ... a unique opportunity for journalists from around the world to ...
... graduate student Brian Zikmund-Fisher was forced into the toughest choice ... few years or endure a bone marrow transplant that could ... now an assistant professor at the University of Michigan School ... After nine months of blood transfusions, a bone marrow match ...
... By Dennis Thompson HealthDay Reporter , TUESDAY, ... smile. What wasn,t to like about a break in the ... and fun? Now fast-forward to your adult life. What ... Some medical experts think it,s not only a good idea ...
... to indicate a racial disparity in the psychological abuse ... African American seniors could be twice as likely to ... also revealed that African American elders could be up ... the survey results in The Gerontologist, the ...
... there may be a way to predict, based on individual ... the investigational new drug tivozanib. This is possible, the ... a new way of creating animal tumor models that mimic ... these studies, they have found a single biomarker that may ...
... Jewish Health has received a US patent for a ... bubble to deliver an antigen and DNA adjuvant. Chairman ... Health Professor of Medicine Steve Dow, PhD, developed the ... of an infectious organism, generally work fine by themselves. ...
Cached Medicine News:Health News:2010 AAO-HNSF miniseminars: Wednesday, Sept. 29, 2010 2Health News:2010 AAO-HNSF miniseminars: Wednesday, Sept. 29, 2010 3Health News:Doctors need to help patients prepare better for health decisions 2Health News:Doctors need to help patients prepare better for health decisions 3Health News:Adding Recess to the Workday Gains Backers 2Health News:Adding Recess to the Workday Gains Backers 3Health News:Adding Recess to the Workday Gains Backers 4Health News:African-American seniors at twice the risk for mental abuse, 5 times for financial exploitation 2Health News:African-American seniors at twice the risk for mental abuse, 5 times for financial exploitation 3Health News:Novel biomarker may predict response to new VEGF receptor inhibitor 2
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
Medicine Products: